The NMPA has accepted the application for the market authorization of the East China Pharmaceutical's innovative topical preparation, Lofucsist Cream 0.05%.

According to East China Pharmaceutical News, on February 2, Hangzhou Zhongmei East China Pharmaceutical Co., Ltd., a wholly-owned subsidiary of East China Pharmaceutical, received a "Notice of Acceptance" issued by the National Medical Products Administration. The application for marketing approval for the 0.05% mometasone cream has been accepted, with the declared indication: suitable for the topical treatment of mild to moderate atopic dermatitis in patients aged 2 to 5 years old.